Daniel Rea

Phase I Pharmacokinetic and Pharmacodynamic Study of the Oral Mammalian Target of Rapamycin Inhibitor Everolimus in Patients With Advanced Solid Tumors

Anne O’Donnell, Sandrine Faivre, Howard A. Burris et al. · Journal of Clinical Oncology · 2008 · 479 citations

Pharmacy, Oncology, Pharmacology +17

aTTom: Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years in 6,953 women with early breast cancer.

Richard Gray, Daniel Rea, Kelly Handley et al. · Journal of Clinical Oncology · 2013 · 450 citations

Medicine, Oncology, Breast Oncology +11

Overall survival in the OlympiA phase III trial of adjuvant olaparib in patients with germline pathogenic variants in BRCA1/2 and high-risk, early breast cancer

Charles E. Geyer, Judy E. Garber, Richard D. Gelber et al. · Annals of Oncology · 2022 · 447 citations · Full text

Medicine, Oncology, Pharmacotherapy +17

Antibacterial Prophylaxis after Chemotherapy for Solid Tumors and Lymphomas

Michael Cullen, Neil Steven, Lucinda Billingham et al. · New England Journal of Medicine · 2005 · 423 citations · Full text

Medicine, Oncology, Pharmacology +17

Adjuvant tamoxifen and exemestane in early breast cancer (TEAM): a randomised phase 3 trial

Cornelis JH van de Velde, Daniel Rea, Caroline Seynaeve et al. · The Lancet · 2011 · 377 citations

Medicine, Oncology, Pharmacology +15